Accelerating Phase 1 Trials: Overcoming API Constraints And Tight Timelines With On-Demand Manufacturing

A European-based clinical-stage development company partnered with Catalent to efficiently execute Phase 1 clinical trials within an ambitious 30-week (7.5-month) timeline, despite facing constraints in active pharmaceutical ingredient (API) availability. The program involved both single-ascending dose (SAD) and multiple-ascending dose (MAD) studies for a poorly soluble API, presenting significant challenges due to the tight schedule and the need to evaluate a broad dose range.

Catalent applied its expertise in lipid-based formulation strategies combined with an on-demand manufacturing approach, providing the flexibility required to support dose escalation across a 75-fold range. This approach not only maximized the use of limited API but also ensured rapid, reliable supply of clinical material, enabling the sponsor to meet all key clinical objectives on schedule. The collaboration highlights how innovative formulation and agile manufacturing solutions can overcome development bottlenecks, accelerate early-stage trials, and support strategic decision-making for complex drug candidates.